RPL23A: A Potential Drug Target and Biomarker (G6147)

Target Name: RPL23A

NCBI ID: G6147

RPL23A

RPL23A: A Potential Drug Target and Biomarker

Ribosomal protein L23a (RPL23A) is a protein that is synthesized in the ribosome, which is a complex of RNA and proteins that synthesizes proteins in the cell. RPL23A is a member of the L23 family of ribosomal proteins, which are known for their ability to interact with small molecules, such as drugs, toxins, and other substances that can affect the structure and function of the ribosome.

RPL23A is a 23-kDa protein that is expressed in most cell types and is involved in various cellular processes, including protein synthesis, translation, and quality control. It is a key protein that contributes to the stability and proper functioning of the ribosome, and is therefore a potential drug target or biomarker.

One of the unique features of RPL23A is its ability to interact with small molecules, such as drugs that can inhibit its activity. This interaction between RPL23A and drugs could make it an attractive target for drug development, as drugs that can inhibit RPL23A activity could be used to treat a variety of diseases.

In addition to its potential as a drug target, RPL23A is also a potential biomarker for certain diseases. For example, RPL23A is expressed in many tissues and cells, including the brain, and has been shown to be involved in various cellular processes, including neurotransmitter synthesis and regulation. Therefore, RPL23A levels may be an indicator of certain neurological diseases, such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

Another potential application of RPL23A is its role in the regulation of protein synthesis. Ribosomes are responsible for synthesizing proteins, and the rate at which they synthesize these proteins can be regulated by various factors, including RPL23A. Therefore, changes in RPL23A levels or activity levels may be an indication of alterations in protein synthesis that could be relevant to a variety of diseases.

In conclusion, RPL23A is a protein that is involved in various cellular processes and has the potential to be a drug target or biomarker. Its ability to interact with small molecules and its role in the regulation of protein synthesis make it an attractive target for further research and development. Further studies are needed to fully understand the potential applications of RPL23A and its potential as a drug or biomarker.

Protein Name: Ribosomal Protein L23a

Functions: Component of the large ribosomal subunit (PubMed:23636399, PubMed:32669547). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399, PubMed:32669547). Binds a specific region on the 26S rRNA (PubMed:23636399, PubMed:32669547). May promote p53/TP53 degradation possibly through the stimulation of MDM2-mediated TP53 polyubiquitination (PubMed:26203195)

The "RPL23A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets